A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia
Carsten Müller-Tidow
◽
Gesine Bug
◽
Michael Lübbert
◽
Alwin Krämer
◽
Jürgen Krauter
◽
...